SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Affymax, Inc. and Takeda Global Research & Development Center, Inc. Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide(TM)/peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses